DUBLIN--(BUSINESS WIRE)--The "Microbiome Therapeutics and Diagnostics, 2nd Edition: Pipeline Analysis and Market Outlook" report has been added to ResearchAndMarkets.com's offering.
From microbes playing a role in our health, the discovery that microbes destroyed the Mayan civilization, to the potential of microbes aiding future interplanetary space exploration, the power of microbes is immense. Since the Human Microbiome Project began, driven by a surge in Next Generation Sequencing (NGS) tools; the human microbiome is drawing interest from Big Pharma, Startups and academia to revolutionize health and disease.
The race is now on to create innovative human microbiome products. However, human microbiome R&D presents numerous challenges. Collaboration is paramount for stakeholders to overcome unique scientific and technology hurdles, manufacturing and regulation challenges, intellectual property barriers and key ethical and social issues, to maximize successful opportunities in this potentially lucrative market.
Several key leading pipeline products will pave the way forward for the future human microbiome market. In 2019, the first biotherapeutics could hit the market with the arrival of Seres Therapeutics/ Nestl Health Science's SER-109 and Rebiotix RBX2660, both for prevention of recurrent C. difficile infection. In 2020, the market could witness the arrival of the first human microbiome diagnostic product, Metabiomics' Colon Polyp and Colon Cancer Test.
Key Topics Covered:
1 Executive Summary
2 Introduction To The Human Microbiome
3 Target Diseases Of Human Microbiome R&D
4 Scientific & Technology Strategies Driving Human Microbiome R&D
5 Major Challenges Of Human Microbiome R&D
6 Business Models Of Key Human Microbiome Players
7 The Human Microbiome Biotherapeutics Pipeline: Key Clinical Candidates
8 The Human Microbiome Diagnostics Pipeline: Key Products In Development
9 The Future Market For Human Microbiome Biotherapeutics & Diagnostics
10 Bibliography
Companies Mentioned
- AO Biome LLC
- Assembly Biosciences
- C3J Therapeutics Inc.
- Enterome Biosciences S.A.
- Finch Therapeutics
- Metabiomics
- Metabogen AB
- Microbiome Therapeutics LLC
- Osel Inc.
- Rebiotix Inc.
- Ritter Pharmaceuticals Inc.
- Second Genome Inc.
- Seres Therapeutics Inc.
- Synlogic Inc.
- Synthetic Biologics Inc.
- Vithera Pharmaceuticals Inc.
- Vedanta Biosciences
- Janssen Research and Development LLC
- Nestle Health Science S.A.
- Pfizer Inc.
- PennCHOP Microbiome Program
- University of Michigan's Host Microbiome Initiative
For more information about this report visit https://www.researchandmarkets.com/research/hnrnf4/microbiome?w=4
